Hong Kong Team Develops Survival-Extending Bird Flu Drug Combo
This article was originally published in PharmAsia News
Executive Summary
A team of Hong Kong researchers has developed a cocktail of drugs it believes could improve H5N1 avian influenza survival rates by a factor of four. The researchers combined GlaxoSmithKline's antiviral drug Relenza (zanamivir) with GD Searle's Celebrex (celecoxib) and Shire's Pentasa (mesalazine) anti-inflammatory drugs. Animal trials showed the combination suppressed the bird-flu virus, extended survival rates and lowered immune-system overreactions. (Click here for more